<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardiovascular</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиоваскулярная терапия и профилактика</journal-title><trans-title-group xml:lang="en"><trans-title>Cardiovascular Therapy and Prevention</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1728-8800</issn><issn pub-type="epub">2619-0125</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.15829/1728-8800-2015-2-31-34</article-id><article-id custom-type="elpub" pub-id-type="custom">cardiovascular-263</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КОРОНАРНАЯ БОЛЕЗНЬ СЕРДЦА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CORONARY HEART DISEASE</subject></subj-group></article-categories><title-group><article-title>СУБФРАКЦИОННЫЙ СПЕКТР ЛИПОПРОТЕИНОВ ВЫСОКОЙ ПЛОТНОСТИ У БОЛЬНЫХ С КОРОНАРНЫМ АТЕРОСКЛЕРОЗОМ</article-title><trans-title-group xml:lang="en"><trans-title>SUBFRACTIONAL SPECTRUM OF HIGH DENSITY LIPOPROTEIDS IN CORONARY ATHEROSCLEROSIS PATIENTS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Озерова</surname><given-names>И. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Ozerova</surname><given-names>I. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.б.н., в.н.с. отдела изучения биохимических маркеров риска ХНИЗ</p></bio><email xlink:type="simple">iozerova@gnicpm.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Метельская</surname><given-names>В. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Metelskaya</surname><given-names>V. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.б.н., профессор, руководитель отдела</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Перова</surname><given-names>Н. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Perova</surname><given-names>N. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, в.н.с. отдела</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гаврилова</surname><given-names>Н. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Gavrilova</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>к.м.н., с.н.с. отдела клинической кардиологии и молекулярной генетики</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Бойцов</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Boytsov</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д.м.н., профессор, директор</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБУ "Государственный научно-исследовательский центр профилактической медицины" Минздрава России. Москва, Россия<country>Россия</country></aff><aff xml:lang="en">FSBI "State Scientific-Research Center for Preventive Medicine" of the Healthcare Ministry. Moscow, Russia<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>20</day><month>04</month><year>2015</year></pub-date><volume>14</volume><issue>2</issue><fpage>31</fpage><lpage>34</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Озерова И.Н., Метельская В.А., Перова Н.В., Гаврилова Н.Е., Бойцов С.А., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Озерова И.Н., Метельская В.А., Перова Н.В., Гаврилова Н.Е., Бойцов С.А.</copyright-holder><copyright-holder xml:lang="en">Ozerova I.N., Metelskaya V.A., Perova N.V., Gavrilova N.E., Boytsov S.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://cardiovascular.elpub.ru/jour/article/view/263">https://cardiovascular.elpub.ru/jour/article/view/263</self-uri><abstract><sec><title>Цель</title><p>Цель. Провести анализ распределения частиц липопротеинов высокой плотности (ЛВП) у больных с коронарным атеросклерозом и выяснить, сопряжены ли особенности субфракционного спектра ЛВП со степенью поражения коронарных артерий. Материалы и методы. В исследование включены 130 пациентов (М/Ж 84/46) 30-80 лет (средний возраст 61,1±9,9 года), которым была проведена коронароангиография. Субфракционный спектр ЛВП определяли с помощью "Липопринт системы" (QuantimetrixLipoprintSystem, США).</p></sec><sec><title>Результаты</title><p>Результаты. Пациенты были разделены на три группы по шкале Gensini: 1 группа (n=40) — коронарное поражение 0-20% — нет кли­нических проявлений коронарной болезни сердца (0 баллов); 2 группа (n=40) — с умеренным поражением коронарных артерий 21-70% (1-34 балла); 3 группа (n=50) — с выраженным поражением коронарных артерий (&gt;35 баллов, 35-176). Пациенты 2 и 3 групп по сравнению с пациентами без коронарного атеросклероза (1 группа) имели более низкие уровни холестерина (ХС), ХС липо­протеинов низкой плотности (ЛНП), аполипопротеина (апо) А! и апо В, а уровень ХС ЛВП и триглицеридов, показатели углеводного обмена (концентрация глюкозы, инсулина и индекс инсулинорези- стентности) и высокочувствительный С-реактивный белок не раз­личались в трех группах, при этом имели более высокую долю мелких плотных ЛВП и промежуточных ЛВП, и более низкую долю крупных ЛВП. Различия в характере распределения частиц ЛВП между пациентами 2 и 3 групп отсутствовали. Заключение. Характер распределения частиц ЛВП, а именно: более высокое относительное содержание мелких плотных и промежуточных частиц ЛВП и более низкая доля крупных частиц ЛВП, ассоциирован с поражением коронарных артерий Сдвиг в субфракционном спектре ЛВП в сторону накопления потенциально проатерогенных частиц ЛВП обнаруживается у пациентов уже на ранних стадиях атеросклероза. </p></sec></abstract><trans-abstract xml:lang="en"><p>Aim. To analyze a dispersion of high density lipoproteid (HDL) particles in patients with coronary atherosclerosis and to find out whether there is a relation of HDL subfractional specifics and severity of coronary lesion. Material and methods. Totally 130 patients included (M/F 84/46) 30-80 y.o. (mean age 61, 1 ±9,9 y.o.), who underwent coronary arteriography. Subfractional spectrum of HDL was assessed by "Lipoprint System" (Quantimetrix Lipoprint System, US). Results. Patients were selected into 3 groups according to Gensini score: 1 group (n=40) — coronary lesion 0-20% — no clinical signs of coronary heart disease (0 points); 2 group (n=40) — moderate lesion 21-70% (1-34 points); 3 group (n=50) — significant lesion (&gt;35 points; 35-176). Patients of the 2 and 3 groups comparing to those without coronary atherosclerosis (1 group) had lower levels of cholesterol (C); C of low density lipoproteids (LDL), apoliporotein (apo) AI and apo B, and the level of HDL-C and triglycerides, carbohydrate metabolism parameters (glucose level, insulin and insulin resistance index) and hi- sensitivity C-reactive protein did not differ in three groups, and had higher portion of smaller dense HDL and intermediate HDL, and less amount of large HDL. The differences in HDL dispersion among 2 and 3 groups patients were not found.</p><sec><title>Conclusion</title><p>Conclusion. A pattern of HDL dispersion, i.e. the higher relative amount of smaller dense particles of HDL and less amount of larger HDL is associated with coronary arteries lesion. Shift in subfractional spectrum of HDL to the side of potentially proatherogenic HDL particles can be found in patients even at earlier stages of atherosclerosis. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>коронарный атеросклероз</kwd><kwd>шкала Gensini</kwd><kwd>суб­фракционный спектр липопротеинов высокой плотности</kwd><kwd>Липопринт система</kwd></kwd-group><kwd-group xml:lang="en"><kwd>coronary atherosclerosis</kwd><kwd>Gensini score</kwd><kwd>subfractional spectrum of high density lipoproteids</kwd><kwd>Lipoprint system</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl. 2011; 12(3): 267-70.</mixed-citation><mixed-citation xml:lang="en">Barter P. HDL-C: role as a risk modifier. Atheroscler Suppl. 2011; 12(3): 267-70.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Karol E. Watson, Beyond LDL-Cholesterol. The Role of Low HDL-Cholesterol and Elevated TG in Residual Cardiovascular Risk Remaining After Statin Therapy. J Manag Care Pharm 2008; 14(8-Suppl): S6-15.</mixed-citation><mixed-citation xml:lang="en">Karol E. Watson, Beyond LDL-Cholesterol. The Role of Low HDL-Cholesterol and Elevated TG in Residual Cardiovascular Risk Remaining After Statin Therapy. J Manag Care Pharm 2008; 14(8-Suppl): S6-15.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Wijtske Annema, Arnold von Eckard. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J 2013; 77: 2432-48.</mixed-citation><mixed-citation xml:lang="en">Wijtske Annema, Arnold von Eckard. High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis. Circ J 2013; 77: 2432-48.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin lipidol 2010; 21(4): 305-11.</mixed-citation><mixed-citation xml:lang="en">Krauss RM. Lipoprotein subfractions and cardiovascular disease risk. Curr Opin lipidol 2010; 21(4): 305-11.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Rizzo M, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? Clin Lab 2009; 55(11-12): 421-9.</mixed-citation><mixed-citation xml:lang="en">Rizzo M, Berneis K, Zeljkovic A, Vekic J. Should we routinely measure low-density and high-density lipoprotein subclasses? Clin Lab 2009; 55(11-12): 421-9.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Krychtiuk KA, Kastl SP, Pfaffenberger S, et al. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis 2014; 237(2): 589-96.</mixed-citation><mixed-citation xml:lang="en">Krychtiuk KA, Kastl SP, Pfaffenberger S, et al. Small high-density lipoprotein is associated with monocyte subsets in stable coronary artery disease. Atherosclerosis 2014; 237(2): 589-96.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">deGoma EM, Rader DJ. High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein? JACC 2012; 60(6): 517-20.</mixed-citation><mixed-citation xml:lang="en">deGoma EM, Rader DJ. High-density lipoprotein particle number: a better measure to quantify high-density lipoprotein? JACC 2012; 60(6): 517-20.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Banuls C, Bellod L, Jover A, et al. Comparability of two different polyacrylamide gel electrophoresis methods for the classification of LDL pattern type. Clin Chim Acta 2012; 413(1-2): 251-7.</mixed-citation><mixed-citation xml:lang="en">Banuls C, Bellod L, Jover A, et al. Comparability of two different polyacrylamide gel electrophoresis methods for the classification of LDL pattern type. Clin Chim Acta 2012; 413(1-2): 251-7.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Oravec S, Dostal E, Dukát A, et al. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Neuro Endocrinol Lett 2011; 32(4): 502-9.</mixed-citation><mixed-citation xml:lang="en">Oravec S, Dostal E, Dukát A, et al. HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Neuro Endocrinol Lett 2011; 32(4): 502-9.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Xu RX, Guo YL, Li XL, et al. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype. Clin Exp Pharmacol Physiol 2014; 41(7): 475-81.</mixed-citation><mixed-citation xml:lang="en">Xu RX, Guo YL, Li XL, et al. Impact of short-term low-dose atorvastatin on low-density lipoprotein and high-density lipoprotein subfraction phenotype. Clin Exp Pharmacol Physiol 2014; 41(7): 475-81.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Utkina EA, Afanasyeva OI, Yezhov MV, et al. Association between different lipoprotein subfractions and coronary atherosclerosis in middle-aged men on statin therapy. Cardiovestnik 2014; 1: 68-76. Russian (Уткина Е.А., Афанасьева О.И., Ежов М.В. и др. Связь различных подфракций липопротеидов с коронарным атеро- склерозом у мужчин среднего возраста, получавших терапию статинами. Кардиологический вестник 2014; 1: 68-76).</mixed-citation><mixed-citation xml:lang="en">Utkina EA, Afanasyeva OI, Yezhov MV, et al. Association between different lipoprotein subfractions and coronary atherosclerosis in middle-aged men on statin therapy. Cardiovestnik 2014; 1: 68-76. Russian (Уткина Е.А., Афанасьева О.И., Ежов М.В. и др. Связь различных подфракций липопротеидов с коронарным атеро- склерозом у мужчин среднего возраста, получавших терапию статинами. Кардиологический вестник 2014; 1: 68-76).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Ozerova IN, Metelskaya VA, Perova NV, et al. Relationship of lipoprotein subfractions with triglycerides level in patients with of different grade of coronary atherosclerosis. Atherosclerosis and dislipidemias 2014; 2(15): 33-7. Russian (Озерова И.Н., Метельская В.А., Перова Н.В. и др. Связь субфракционного спектра липопротеинов низких плотностей с уровнем триглицеридов в крови при разной степени стенозов коронарных артерий. Атеросклероз и дислипидемии 2014; 2(15): 33-7).</mixed-citation><mixed-citation xml:lang="en">Ozerova IN, Metelskaya VA, Perova NV, et al. Relationship of lipoprotein subfractions with triglycerides level in patients with of different grade of coronary atherosclerosis. Atherosclerosis and dislipidemias 2014; 2(15): 33-7. Russian (Озерова И.Н., Метельская В.А., Перова Н.В. и др. Связь субфракционного спектра липопротеинов низких плотностей с уровнем триглицеридов в крови при разной степени стенозов коронарных артерий. Атеросклероз и дислипидемии 2014; 2(15): 33-7).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Gavrilova NE, Metelskaya VA, Perova NV, et al. Selection for the quantitative evaluation method of coronary arteries based upon comparative analysis of angiographic scales. Russ J Cardiol 2014; 6(110): 24-9. Russian (Гаврилова Н.Е., Метельская В.А., Перова Н.В. и др. Выбор метода количественной оценки поражения коронарных артерий на основе сравнительного анализа ангиографических шкал. Российский кардиологический журнал 2014; 6(110): 24-9).</mixed-citation><mixed-citation xml:lang="en">Gavrilova NE, Metelskaya VA, Perova NV, et al. Selection for the quantitative evaluation method of coronary arteries based upon comparative analysis of angiographic scales. Russ J Cardiol 2014; 6(110): 24-9. Russian (Гаврилова Н.Е., Метельская В.А., Перова Н.В. и др. Выбор метода количественной оценки поражения коронарных артерий на основе сравнительного анализа ангиографических шкал. Российский кардиологический журнал 2014; 6(110): 24-9).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Brunzell JD, Zambon A, Deeb SS. The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. Biochim Biophys Acta 2012; 1821(3): 365-72.</mixed-citation><mixed-citation xml:lang="en">Brunzell JD, Zambon A, Deeb SS. The effect of hepatic lipase on coronary artery disease in humans is influenced by the underlying lipoprotein phenotype. Biochim Biophys Acta 2012; 1821(3): 365-72.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Kannel WB, Vassan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol 2009; 24 (4): 345-50.</mixed-citation><mixed-citation xml:lang="en">Kannel WB, Vassan RS. Triglycerides as vascular risk factors: new epidemiologic insights. Curr Opin Cardiol 2009; 24 (4): 345-50.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
